Couple of Questions29 Sep 2020 13:30
Afternoon All
Have been reading this board for a couple of months now
Don't consider myself a LTH, but brought in and everwhere in between 23.9p & £3 (ave 106), so have been around a while.
Really looking forward to approvals, but from the recent RNS's not too sure whether this whole new end to end product with Beckman needs it's own approval post validation, or the approval mentioned relates entirely to Saliva not Swab. Can anyone clarify this?
With our product India isn't going to be a massive market for us; anyone who knows about the indian government will know it's indian products 1st, then the cheapest, finally the best value for money (GDR). This looks like their big seller, but even the small portion of their market we get will be massive for us: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/indias-low-cost-coronavirus-test-feluda-here-is-how-it-will-work-and-why-it-is-said-to-be-more-efficient/articleshow/78228479.cms
One Thing is clear, until we get sales data we won't take off. what the company Valued us at is 80p per share last time they raised cash, therefore this is the default price MM's will work back down to until we get any income.
Seen a bit about partial conversion of the convertable bond this week. With the end of year results around the corner this is typical, after raising enough cash to see us through until Production, they now want to reduce debt so our end numbers look a little better in light not having any sales.
Also not seen many people factor in we now have 2 partners now (which will be taking a cut), does anyone have an idea of our actul profit per product sold? For those who can stick it out, it is likely to come, when is the question